• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重组人组织型纤溶酶原激活剂与人类单链尿激酶型纤溶酶原激活剂的协同组合。对严重狭窄犬冠状动脉血栓形成模型中溶栓及再闭塞的影响。

Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.

作者信息

Ziskind A A, Gold H K, Yasuda T, Kanke M, Guerrero J L, Fallon J T, Saito T, Collen D

机构信息

Cardiac Division, Massachusetts General Hospital, Boston 02114.

出版信息

Circulation. 1989 Feb;79(2):393-9. doi: 10.1161/01.cir.79.2.393.

DOI:10.1161/01.cir.79.2.393
PMID:2492455
Abstract

The synergistic effects of recombinant human tissue-type plasminogen activator (rt-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on coronary arterial thrombolysis were investigated in open-chest dogs with thrombosis of the left anterior descending coronary artery and a superimposed high-grade stenosis. A 90% stenosis was generated by external constriction, reducing blood flow to 40 +/- 10% of baseline. Localized thrombosis was produced by endothelial cell injury and instillation of thrombin and fresh blood. Intravenous infusion for 60 minutes of either 30 micrograms/kg/min rt-PA alone or 10 micrograms/kg/min scu-PA alone consistently produced coronary artery recanalization (six of eight dogs and five of five dogs, respectively) but was almost always associated with reocclusion during or shortly after the end of the infusion (four of six dogs and five of five dogs, respectively). Infusion of either 15 micrograms/kg/min rt-PA or 5 micrograms/kg/min scu-PA for 60 minutes did not cause coronary artery recanalization (none of four dogs in each group). Combined infusion of 7.5 micrograms/kg/min rt-PA and 2.5 micrograms/kg/min scu-PA for 60 minutes (one fourth of the minimum thrombolytic dose of each agent) induced coronary artery recanalization (six of six dogs) but was also associated with early reocclusion (six of six dogs). Combined infusion of 3.75 micrograms/kg/min rt-PA and 1.25 micrograms/kg/min scu-PA for 60 minutes did not consistently cause recanalization (one of four dogs). Combined infusion of 15 micrograms/kg/min rt-PA and 5 micrograms/kg/min scu-PA for 60 minutes caused recanalization in all of six dogs but was associated with reocclusion in all six.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

在开胸的、左前降支冠状动脉有血栓形成且合并严重狭窄的犬中,研究了重组人组织型纤溶酶原激活剂(rt-PA)和单链尿激酶型纤溶酶原激活剂(scu-PA)对冠状动脉溶栓的协同作用。通过外部压迫造成90%的狭窄,使血流减少至基线的40±10%。通过内皮细胞损伤以及注入凝血酶和新鲜血液产生局部血栓。单独静脉输注60分钟,剂量为30微克/千克/分钟的rt-PA或10微克/千克/分钟的scu-PA均能持续使冠状动脉再通(分别为8只犬中的6只和5只犬中的5只),但几乎总是在输注结束时或结束后不久出现再闭塞(分别为6只犬中的4只和5只犬中的5只)。以15微克/千克/分钟的rt-PA或5微克/千克/分钟的scu-PA输注60分钟未引起冠状动脉再通(每组4只犬均无)。以7.5微克/千克/分钟的rt-PA和2.5微克/千克/分钟的scu-PA联合输注60分钟(每种药物最小溶栓剂量的四分之一)可诱导冠状动脉再通(6只犬中的6只),但也伴有早期再闭塞(6只犬中的6只)。以3.75微克/千克/分钟的rt-PA和1.25微克/千克/分钟的scu-PA联合输注60分钟不能持续引起再通(4只犬中的1只)。以15微克/千克/分钟的rt-PA和5微克/千克/分钟的scu-PA联合输注60分钟使所有6只犬均出现再通,但所有6只犬均出现再闭塞。(摘要截短于250字)

相似文献

1
Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.重组人组织型纤溶酶原激活剂与人类单链尿激酶型纤溶酶原激活剂的协同组合。对严重狭窄犬冠状动脉血栓形成模型中溶栓及再闭塞的影响。
Circulation. 1989 Feb;79(2):393-9. doi: 10.1161/01.cir.79.2.393.
2
Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
Thromb Res. 1988 Jul 1;51(1):63-74. doi: 10.1016/0049-3848(88)90283-6.
3
A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis.一种用于研究溶栓后再血栓形成的冠状动脉血栓形成叠加高度狭窄的犬模型。
J Am Coll Cardiol. 1989 May;13(6):1409-14. doi: 10.1016/0735-1097(89)90319-7.
4
Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.使用选择性Xa因子抑制剂蜱抗凝肽联合增强酶促溶栓作用并预防血栓再闭塞。在犬急性冠状动脉血栓形成模型中与水蛭素和肝素的比较。
Circulation. 1992 Feb;85(2):805-15. doi: 10.1161/01.cir.85.2.805.
5
Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
J Cardiovasc Pharmacol. 1987 Jan;9(1):91-3.
6
Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.组织型纤溶酶原激活剂(t-PA)、单链尿激酶型纤溶酶原激活剂(scu-PA)和尿激酶序贯输注对兔颈静脉血栓形成模型溶栓的协同作用。
Thromb Haemost. 1987 Oct 28;58(3):943-6.
7
Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.重组单链尿激酶型纤溶酶原激活剂(沙芦普酶)静脉推注或持续输注用于溶栓的比较。犬冠状动脉和股静脉联合血栓形成模型。
Blood. 1990 Oct 15;76(8):1558-63.
8
Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis.
J Am Coll Cardiol. 1986 Jul;8(1):118-24. doi: 10.1016/s0735-1097(86)80101-2.
9
Additional myocardial salvage by coadministration of the epoprostenol analog taprostene to recombinant single-chain urokinase-type plasminogen activator in a canine coronary thrombosis model.在犬冠状动脉血栓形成模型中,将依前列醇类似物他前列烯与重组单链尿激酶型纤溶酶原激活剂联合使用实现额外的心肌挽救。
Arzneimittelforschung. 1989 Apr;39(4):534-8.
10
Molecular mechanism of action of newer thrombolytic agents.新型溶栓药物的分子作用机制
J Am Coll Cardiol. 1987 Nov;10(5 Suppl B):11B-15B. doi: 10.1016/s0735-1097(87)80422-9.

引用本文的文献

1
2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 6: Defining rational use of thrombolytics.2022 年兽医重症监护领域抗栓和溶栓药物合理应用共识更新(CURATIVE)第六域:定义溶栓药物的合理应用。
J Vet Emerg Crit Care (San Antonio). 2022 Jul;32(4):446-470. doi: 10.1111/vec.13227.
2
Cardiology.心脏病学
Postgrad Med J. 1990 Apr;66(774):263-79. doi: 10.1136/pgmj.66.774.263.